ITCI insider transaction filings
Intra-Cellular Therapies, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-04-02. Screen ITCI transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ITCI between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Intra-Cellular Therapies, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-04-02 | 4 | Salas Eduardo Rene — Director | Disposition to issuer (D): 1,567 @ $132 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 16,757 (derivative) · Disposition to issuer (D): 7,009 (derivative) · Disposition to issuer (D): 4,322 (derivative) · Disposition to issuer (D): 2,951 (derivative) | EDGAR |
| 2025-04-02 | 4 | Neumann Mark — EVP, Chief Commercial Officer | Disposition to issuer (D): 52,811 @ $132 · Disposition to issuer (D): 17,916 (derivative) · Disposition to issuer (D): 13,133 (derivative) · Disposition to issuer (D): 17,485 (derivative) · Disposition to issuer (D): 22,727 (derivative) · Grant/award (A): 13,134 (derivative) @ $0 · +3 more | EDGAR |
| 2025-04-02 | 4 | Mates Sharon — Chairman and CEO, Director | Disposition to issuer (D): 945,235 @ $132 · Disposition to issuer (D): 190,000 @ $132 · Disposition to issuer (D): 86,003 (derivative) · Disposition to issuer (D): 135,399 (derivative) · Disposition to issuer (D): 138,473 (derivative) · Disposition to issuer (D): 66,886 (derivative) · +9 more | EDGAR |
| 2025-04-02 | 4 | Durgam Suresh K. — EVP, Chief Medical Officer | Disposition to issuer (D): 42,913 @ $132 · Disposition to issuer (D): 53,967 (derivative) · Disposition to issuer (D): 33,443 (derivative) · Disposition to issuer (D): 18,714 (derivative) · Disposition to issuer (D): 17,916 (derivative) · Disposition to issuer (D): 13,133 (derivative) · +6 more | EDGAR |
| 2025-04-02 | 4 | Narula Sanjeev — Executive Vice President & CFO | Disposition to issuer (D): 17,251 (derivative) · Disposition to issuer (D): 35,046 (derivative) · Disposition to issuer (D): 22,727 (derivative) | EDGAR |
| 2025-04-02 | 4 | Halstead Michael — President | Disposition to issuer (D): 21,307 @ $132 · Disposition to issuer (D): 40,472 (derivative) · Disposition to issuer (D): 17,916 (derivative) · Disposition to issuer (D): 13,133 (derivative) · Disposition to issuer (D): 24,478 (derivative) · Disposition to issuer (D): 45,454 (derivative) · +4 more | EDGAR |
| 2025-04-02 | 4 | VAN NOSTRAND ROBERT L — Director | Disposition to issuer (D): 11,340 @ $132 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · +4 more | EDGAR |
| 2025-04-02 | 4 | MARCUS JOEL S — Director | Disposition to issuer (D): 48,238 @ $132 · Disposition to issuer (D): 10,000 @ $132 · Disposition to issuer (D): 4,322 (derivative) · Disposition to issuer (D): 2,951 (derivative) | EDGAR |
| 2025-04-02 | 4 | RIGGS RORY B — Director | Disposition to issuer (D): 131,512 @ $132 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 16,757 (derivative) · +3 more | EDGAR |
| 2025-03-31 | 4 | Mates Sharon — Chairman and CEO, Director | Gift (G): 190,000 @ $0 · Gift (G): 190,000 @ $0 | EDGAR |
| 2025-03-10 | 4 | Neumann Mark — EVP, Chief Commercial Officer | Option exercise (M): 13,133 · Tax withholding (F): 5,572 @ $131.19 · Option exercise (M): 7,345 · Tax withholding (F): 3,116 @ $131.24 · Option exercise (M): 13,133 (derivative) @ $0 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Durgam Suresh K. — EVP, Chief Medical Officer | Option exercise (M): 13,133 · Tax withholding (F): 5,572 @ $131.19 · Option exercise (M): 7,345 · Tax withholding (F): 3,116 @ $131.24 · Option exercise (M): 13,133 (derivative) @ $0 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 40,712 · Tax withholding (F): 19,848 @ $131.19 · Option exercise (M): 20,566 · Tax withholding (F): 10,129 @ $131.24 · Option exercise (M): 40,712 (derivative) @ $0 · Option exercise (M): 20,566 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Halstead Michael — President | Option exercise (M): 13,133 · Tax withholding (F): 6,718 @ $131.19 · Option exercise (M): 7,345 · Tax withholding (F): 3,757 @ $131.24 · Option exercise (M): 13,133 (derivative) @ $0 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 34,969 · Tax withholding (F): 16,978 @ $128.20 · Option exercise (M): 34,969 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Neumann Mark — EVP, Chief Commercial Officer | Option exercise (M): 8,742 · Tax withholding (F): 3,709 @ $128.20 · Option exercise (M): 8,742 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Durgam Suresh K. — EVP, Chief Medical Officer | Option exercise (M): 8,742 · Tax withholding (F): 3,709 @ $128.20 · Option exercise (M): 8,742 (derivative) @ $0 | EDGAR |
| 2025-03-04 | 4 | Halstead Michael — President | Option exercise (M): 12,239 · Tax withholding (F): 6,261 @ $128.20 · Option exercise (M): 12,239 (derivative) @ $0 | EDGAR |
| 2025-02-26 | 4 | MARCUS JOEL S — Director | Option exercise (M): 7,009 @ $63.79 · Option exercise (M): 7,009 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Mates Sharon — Chairman and CEO, Director | Grant/award (A): 30,847 @ $0 · Tax withholding (F): 15,233 @ $127 · Grant/award (A): 121,212 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Neumann Mark — EVP, Chief Commercial Officer | Grant/award (A): 11,017 @ $0 · Tax withholding (F): 4,729 @ $127 · Grant/award (A): 22,727 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Durgam Suresh K. — EVP, Chief Medical Officer | Grant/award (A): 11,017 @ $0 · Tax withholding (F): 4,730 @ $127 · Grant/award (A): 24,621 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Narula Sanjeev — Executive Vice President & CFO | Grant/award (A): 22,727 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Halstead Michael — President | Grant/award (A): 11,017 @ $0 · Tax withholding (F): 5,691 @ $127 · Grant/award (A): 45,454 (derivative) @ $0 | EDGAR |
| 2025-01-03 | 4 | RIGGS RORY B — Director | Grant/award (A): 215 @ $83.52 | EDGAR |
| 2024-12-06 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 51,000 @ $12.73 · Sale (S): 27,667 @ $85.62 · Sale (S): 23,333 @ $86.00 · Option exercise (M): 51,697 @ $12.73 · Sale (S): 50,163 @ $84.06 · Sale (S): 1,534 @ $84.69 · +2 more | EDGAR |
| 2024-11-14 | 4 | Halstead Michael — President | Option exercise (M): 22,869 @ $23.94 · Sale (S): 15,105 @ $88.72 · Sale (S): 6,116 @ $89.63 · Sale (S): 1,648 @ $90.89 · Option exercise (M): 18,714 @ $36.89 · Sale (S): 13,371 @ $88.17 · +3 more | EDGAR |
| 2024-10-15 | 4 | RIGGS RORY B — Director | Option exercise (M): 14,189 · Option exercise (M): 14,189 (derivative) @ $0 | EDGAR |
| 2024-10-02 | 4 | RIGGS RORY B — Director | Grant/award (A): 246 @ $73.17 | EDGAR |
| 2024-08-30 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 35,604 @ $12.73 · Sale (S): 29,832 @ $72.44 · Sale (S): 5,772 @ $73.25 · Option exercise (M): 34,396 @ $12.73 · Sale (S): 28,203 @ $72.73 · Sale (S): 6,193 @ $73.32 · +2 more | EDGAR |
| 2024-08-28 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 22,713 @ $17.57 · Sale (S): 22,713 @ $74.59 · Option exercise (M): 40,513 @ $17.57 · Sale (S): 23,657 @ $73.33 · Sale (S): 16,856 @ $73.93 · Option exercise (M): 32,699 @ $17.57 · +5 more | EDGAR |
| 2024-08-23 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 53,013 @ $17.57 · Sale (S): 44,134 @ $75.40 · Sale (S): 4,297 @ $76.20 · Sale (S): 2,682 @ $77.21 · Sale (S): 1,900 @ $77.98 · Option exercise (M): 39,380 @ $17.57 · +7 more | EDGAR |
| 2024-08-20 | 4 | Neumann Mark — EVP, Chief Commercial Officer | Option exercise (M): 18,714 @ $36.89 · Sale (S): 18,714 @ $75.08 · Option exercise (M): 18,714 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Narula Sanjeev — Executive Vice President & CFO | Grant/award (A): 17,251 (derivative) @ $0 · Grant/award (A): 35,046 (derivative) @ $0 | EDGAR |
| 2024-07-02 | 4 | VAN NOSTRAND ROBERT L — Director | Grant/award (A): 83 @ $68.49 | EDGAR |
| 2024-07-02 | 4 | RIGGS RORY B — Director | Grant/award (A): 262 @ $68.49 | EDGAR |
| 2024-06-25 | 4 | Salas Eduardo Rene — Director | Option exercise (M): 1,567 · Option exercise (M): 1,567 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | VAN NOSTRAND ROBERT L — Director | Option exercise (M): 1,567 · Option exercise (M): 1,567 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | MARCUS JOEL S — Director | Option exercise (M): 1,567 · Option exercise (M): 1,567 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | RIGGS RORY B — Director | Option exercise (M): 1,567 · Option exercise (M): 20,000 @ $16.86 · Sale (S): 4,462 @ $75.57 · Option exercise (M): 1,567 (derivative) @ $0 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | VAN NOSTRAND ROBERT L — Director | Option exercise (M): 20,000 @ $16.86 · Sale (S): 8,891 @ $75.71 · Sale (S): 11,109 @ $76.07 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Salas Eduardo Rene — Director | Grant/award (A): 2,951 (derivative) @ $0 · Grant/award (A): 4,322 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | VAN NOSTRAND ROBERT L — Director | Grant/award (A): 2,951 (derivative) @ $0 · Grant/award (A): 4,322 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | MARCUS JOEL S — Director | Grant/award (A): 2,951 (derivative) @ $0 · Grant/award (A): 4,322 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | RIGGS RORY B — Director | Grant/award (A): 2,951 (derivative) @ $0 · Grant/award (A): 4,322 (derivative) @ $0 | EDGAR |
| 2024-04-25 | 4 | Mates Sharon — Chairman and CEO, Director | Option exercise (M): 8,638 @ $16.86 · Option exercise (M): 11,382 @ $17.57 · Option exercise (M): 8,638 (derivative) @ $0 · Option exercise (M): 11,382 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | VAN NOSTRAND ROBERT L — Director | Grant/award (A): 79 @ $69.20 | EDGAR |
| 2024-04-02 | 4 | RIGGS RORY B — Director | Grant/award (A): 260 @ $69.20 | EDGAR |
| 2024-03-22 | 4 | RIGGS RORY B — Director | Option exercise (M): 20,000 @ $18.56 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Halstead Michael — EVP and General Counsel | Sale (S): 12,912 @ $66.14 · Sale (S): 220 @ $66.81 · Option exercise (M): 7,345 · Sale (S): 6,107 @ $65.82 · Sale (S): 1,238 @ $66.70 · Option exercise (M): 7,345 (derivative) @ $0 | EDGAR |
Recent 8-K events — Intra-Cellular Therapies, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-04-02 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-27 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-03-18 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-03-03 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-02-21 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-12-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-05 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-10-30 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ITCI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →